FIFARMA

IQVIA

Patient W.A.I.T Indicator 2023 LATAM

Argentina

AN ASSESSMENT OF INNOVATIVE MEDICINES AVAILABILITY ACROSS LATIN AMERICA



MARCH
2024

Table of contents

Summary of key findings from the study

Availability in Argentina vs LATAM region

- 57% of molecules are globally approved in at least one country in LATAM, 20% are privately available, 34% have limited availability, and 45% are fully available
- In Argentina, 90% of molecules that are approved have at least private, limited or fully availability with a majority (69% or 47 molecules) having only private availability, mostly based on case-by-case decisions
- More orphan molecules are approved (85 orphan vs 67 oncology) in at least one country in LATAM- this trend carries through to Argentina (50 orphan vs 48 oncology)
- Though a larger number of orphan molecules are available, oncology molecules boast higher rates of availability in Argentina
    - 92% of oncology molecules vs 88% orphan molecules that are approved in Argentina have at least private, limited or full availability with a majority (77% oncology and 70% orphan) maintaining only private availability

Though many molecules face reimbursement restrictions and uncertainty surrounding systemic changes exists, ***Argentina performs better than LATAM regional averages***

Availability Timelines in Argentina vs LATAM region

Time to availability *represents the length of time from both global and local market authorization until full or limited availability is reached*

- Time to local approval/market authorization on average in LATAM is 953 days, where time to availability (between marketing authorization and availability) is on average 1,641 days
- Argentina is the country with the second shortest regulatory and approval timelines overall, and first in availability timelines*
- Time to availability for orphan molecules are slightly faster in LATAM on average (1,637 days vs 1,700 days), and Argentina follows a similar trend with 1,027 days to availability for orphan molecules and 889 days to availability for oncology molecules

Availability over time *pinpoints the degree of availability according to global market authorization year to estimate the maturity of available molecules*

- Availability over time reflects these trends and is likely to also have been affected by COVID: most molecules with full availability status were approved in Argentina between 2014-2017 (100%)

Note: Global availability is defined as a molecule that has regulatory approval in the United States of America, or in Europe; *Argentina and Costa Rica had a reduced dataset for timelines and may not reflect them accurately

Argentina boasts a higher number and higher percentage of orphan molecules available vs oncology molecules

Regional extended availability (2014-2021) – Regional and Argentina



- Of the 108 molecules approved in at least one country in LATAM, 20% are privately available, 34% have limited availability, and 45% are fully available
- In Argentina, 90% of molecules that are approved have at least private, limited or full availability with a majority (69% or 47 molecules) having only private availability
- 67 oncology molecules are approved in at least one country in LATAM, while 25% are privately available, 28% have limited availability, and 46% are fully available
- 95% of oncology molecules that are approved in Argentina have at least private or limited availability with a majority (77% or 37 molecules) having limited availability
- More orphan molecules are approved (85 orphan vs 67 oncology) in at least one country in LATAM, while 18% are privately available, 39% have limited availability, and 44% are fully available
- As LATAM regionally, there are more orphan molecules available than oncology molecules (50 vs 48 and higher rate of available oncology molecules as well (92% vs 88%)

+

*Although the availability **regionally reaches 83%**, Argentina performs strongly at **90% combined availability**, with similar rates between orphan and oncology*

*Note: Global availability is defined as a molecule that has regulatory approval in the USA, or in Europe;*Approved in at least one LATAM country*
[1] Not considering Argentina extended availability as a result of its fragmented private market based on case-by-case decisions
**Orphan molecules do not match local legislation's total since various sources of information were utilized for the study, and designation for selection was based on US/EU criteria, not local. These sources are listed in the document's appendix*

Length of time to availability varies regionally in LATAM, with Argentina having long regulatory but short availability timelines

Average time to availability (2014-2021) – Regional and Argentina, FDA / EMA, marketing auth., and local availability dates



- Wide disparities exist between countries in terms of time to availability, with Argentina on the low end at an average of 966 days, Colombia towards the middle with 1,673 days, Brazil with 1,604 days and Mexico on the high end, with an average of 2,073 days, which reflects the total of time to marketing authorization and time to reimbursement (pub / pri), as of FDA/EMA approval
- Time to local approval/market authorization on average in LATAM is 953 days, where time to availability (between marketing authorization and availability is on average 1,641 days)
- Argentina is the second country with the shortest regulatory and approval timelines overall and first in availability timelines as a result of a developed access pathway through private plans, yet still restricted to only a subset of the population
- Time to availability for orphan molecules are slightly faster than oncology molecules in LATAM on average (1,638 days vs 1,700 days), and Argentina follows a similar trend with 1,027 days to availability for orphan molecules and 889 days to availability for oncology molecules

\+

*Argentina has a relatively quick **time to availability** as a result of a developed access pathway through private plans; **Oncology molecules** become available faster than **Orphan molecules** on average, although slower than Orphan non-Onco*

[1] *Global approval date considered the earliest date between FDA or EMA*
[2] *Considering molecules with Full and / or Limited Availability*
[2] *ARG / CRI: Limited number of Fully / Limited Availability date of reimbursement information resulted in shorter timelines*
**Orphan category includes Orphan Oncology molecules*

The overall trend observed regionally in LATAM remains similar in Argentina for both oncology and orphan molecules over time

Extended availability over time (2014-2021) – Regional and Argentina

Combined

As seen regionally in LATAM**, most molecules with limited availability status **were approved in Argentina between 2014-2017



Oncology



Orphan



Approved / Commercialized | Limited availability | Regional availability
Full availability | Only privately available | Not available-Approved

- As was observed regionally in LATAM, most molecules with full availability status were approved in Argentina between 2014-2017 (100% of the total molecules with full availability)
- Similar trends are seen for molecules that are fully available between 2014-2017 in Argentina at the oncology (92%) and orphan (88%) level
- A number of potential drivers can explain this; in addition to the generally long, fragmented path to availability, three additional potential issues are:
    - The COVID-19 pandemic and associated strain on healthcare system likely exacerbating underlying systemic challenges e.g., budget impact
    - Increases in investment coupled with clinical innovation in oncology/rare disease in recent years has led to new standards of care e.g., PD1s, CDK4/6 inhibitors (2014-2015), but also more gradual increments of clinical benefit, and lesser priority for reimbursement
    - Expanding indications, going from most niche or smallest patient population to broader more prevalent conditions

In recent years, the number of fully available molecules has decreased, together with molecule approvals

Key drivers of availability in Argentina

Four main drivers emerge when analyzing availability of orphan and oncology molecules in Argentina

1. Argentina is a relatively large market within the LATAM region, generally with local presence of multinational manufacturers and local teams dedicated to market access in the country

2. The mature private market enables access, mainly in case-by-case reimbursement decisions, amidst a highly fragmented payer system which presents significant challenges to availability outside of the private sector; local market access teams generally require a complex account-level access strategy post-regulatory approval

3. In 2016, the Plan for Universal Health Care (Cobertura Universal de la Salud, CUS) was introduced to reduce inequalities in healthcare and improve access to essential medicines, however results did not show a marked trend post-implementation in public access to innovative medicines, with important differences still existing between provinces, limiting fully available molecules.

4. Future systemic changes will likely impact availability of high-cost, novel molecules with the recent change in administration and high degree of uncertainty around the economic conditions in the coming years; austerity is expected in the short term.

About the authors

Overall Project Leader

Andre Ballalai
Associate Principal
IQVIA | Value & Access

André Ballalai is a researcher in the field of International Health Systems and Policy and Global Director of Value and Access Consulting at IQVIA in New York, USA.

He has more than 15 years of experience at companies such as Roche and IQVIA, where he currently develops value-based healthcare projects, alternative financing models and health policy strategies in various geographies, including the US and emerging economies such as the Americas. Latin, Middle East and Asia.

He has a bachelor's degree in Chemical Engineering from UFPR (Federal University of Paraná) and a specialization in Financial Management from Insper

Regional Project Manager

Oscar Courtney
Manager
IQVIA | Value & Access

Oscar Courtney is a Manager in the Value and Access center of excellence supporting commercial, strategy and market access projects.

Oscar has over 7 years of consulting experience, with the last 3 at IQVIA working with global pharma companies.

Oscar graduated with a Bachelor of Commerce in Marketing and Bachelor of Science in Psychology from the University of New South Wales, Australia.

Co-Authors and Contributors

IQVIA Project Team and Co-Authors

Jessica Lopez
Associate Consultant
IQVIA | Strategy Consulting

Jessica Lopez is an Associate Consultant within IQVIA's consulting practice in New York, USA.

She has experience managing different value-based health projects in various geographies, including the US and emerging economies such as Latin America, the Middle East, and Asia.

Jessica holds a degree in Socio-Cultural Anthropology from Haverford College.

Rosa de Lourdes Bonilla
Consultant
IQVIA | Strategy Consulting

Rosa de Lourdes Bonilla is a Consultant within IQVIA's consulting practice in Mexico City, MX.

She has 6 years of financial consulting experience prior to IQVIA. Rosa holds a bachelor's degree in Economics from Instituto Tecnologico Autonomo de Mexico (ITAM), Mexico City, and a degree in Political EU Economy from the London School of Economics.

Regional Contributors and Co-Authors

Silvana Lay
Director of Access & Public Affairs, **Fifarma**

Silvana is the Corporate Affairs Director at FIFARMA, the Latin America association of the innovative pharmaceutical industry. She has over fifteen years of management experience. Silvana is a forestry Engineer with a Master of Business Administration (M.B.A.) focused on International Business from Tulane University - A.B. Freeman School of Business.

Diego Guarin
President of Regional Chapter
ISPOR LATAM

Dr. Diego Guarin is the Regional Market Access Lead for LATAM and is a founding member of the ISPOR Colombia chapter, also having served as chair of the ISPOR Latin American Consortium Industry Committees and Advisory Board. Dr. Guarin graduated as Medical Doctor from Universidad del Rosario-1653 (Colombia) and holds various master's degrees.

Francisca Rodriguez
Gerente de Inovacion y Salud,
CIF Chile

Francisca currently works at the Chamber of Pharmaceutical Innovation where she promotes high standards of industry relations, encouraging greater investment in R&D by the industry in Chile. She is a Medical Epidemiologist with degrees from Universidad del Desarollo, Universidad de Chile, and Unidversidad de los Andes.

Acknowledgements

The completion of this study could not have been possible without the support of numerous stakeholders across all countries included on the research

FIFARMA Leadership

Yaneth Giha

Executive Director

Maria Alejandra De Guzman

Operations and Communications Director

Manufacturer associations and their local representatives

Karla Baez - AMIIF

- kbaez@amiif.org.mx

Roy Benchimol - CAEME

- roy.benchimol@caeme.org.ar

Catalina Bello Durán - AFIDRO

- cbello@afidro.org

Francisca Rodriguez - CIF CHILE

- francisca.rodriguez@cifchile.cl

Edgar Tenorio - FEDEFARMA

- edgar.tenorio@fedefarma.org

Renata Nunes - INTERFARMA

- renata.nunes@interfarma.org.br

Gonzalo Marrero- ALAFARPE

- gmarrero@alafarpe.org.pe

Álvaro Maldonado - IFI

- amaldonado@ifi-promesa.com.ec

IQVIA country experts based locally

Argentina

Brazil

Chile

Ecuador

Costa Rica

Ecuador

Mexico

Peru

Regional LATAM

Notes on Sources

THIS REPORT IS BASED ON THE SOURCES DETAILED BELOW

IQVIA MIDAS™ is a unique platform for assessing worldwide healthcare markets. It integrates IQVIA's national audits into a globally consistent view of the pharmaceutical market, tracking virtually every product in hundreds of therapeutic classes and provides estimated product volumes, trends and market share through retail and non-retail channels. MIDAS data is updated monthly and retains 12 years of history. IQVIA MIDAS was used by each local IQVIA team to provide the existing data

PUBLIC AVAILABLE INFORMATION for each market was incorporated in the study from HTA agencies and regulatory bodies

Argentina: ANMAT

MANUFACTURERS' INTERNAL DATA was asked via a Smartsheet survey and collected from each of the manufacturers included in the study

MANUFACTURERS ASSOCIATIONS' DATA as well as MNFs data, was asked and collected from associations included in the study. Associations also participated in the local definition's alignment. Associations that participated are:

Argentina: CAEME

2022 W.A.I.T INDICATOR STUDY data was also leveraged to include and validate for the 2023 W.A.I.T Indicator results. Data was included in order to expand the cohort to 7 years (2014-2021)

Data was validated and QCed across all sources by a data analysis model generating comprehensive and visual results

Definitions & Methodologies

Molecules were selected from US/EU approvals for novel oncologics and molecules indicated in rare disease from 2014-2021

1. Molecules with global approval from 2014-2021 were first identified via IQVIA's global list and EFPIA WAIT list
2. List was narrowed to include only orphan and oncology molecules
3. Some molecules were further excluded if they fell into the following categories: diagnostic tools, vaccines, drugs used in symptom relief (e.g., nausea) associated with oncologic treatment, molecules launched outside of the US/EU

- A few additional points were noted: (a) Molecules can have up to three marketing authorization dates: FDA, EMA, and (b) local Orphan status may be determined by either the FDA or EMA

Results from the study are shown in terms of different levels of availability and compared across countries

1. ***No Availability: Not submitted, or in regulatory evaluation process***
   - Time required by local regulatory bodies evaluating market authorization submissions to make a final approval publicly available.
2. ***Approved, not available: Commercially available, but not reimbursed***
   - As being approved by regulatory bodies, medicines are authorized to be commercialized in the country. In this stage, there is reimbursement from neither private nor public payers; patients typically pay full OOP. This is inclusive of managed access schemes.
3. ***Privately available: Private market reimbursement***
   - Medicines available only in the private market for a limited number of patients. Typically, medicines are reimbursed by private payers (e.g., HMOs) or have total or partial coverage by private insurance policies.
4. ***Limited availability: Reimbursement but not for a broad population***
   - Medicines available only in the private market for a limited number of patients. Typically, medicines are reimbursed by private payers (e.g., HMOs) or have total or partial coverage by private insurance policies.
5. ***Full availability: Broad and national reimbursement***
   - Medicines are fully available at national level for a broad population in both public and private market. Full availability is frequently tied to national formulary listing, positive HTA recommendations, or central procurement.

Each geography in scope has a local definition of availability such that, to the extent possible, results can be compared regionally

- ***Ecuador Definitions of availability:*** full: Essential list e.g., MSP, IESS; limited: Typically exception processes; private: n/a



CONTACT US

Andre Ballalai, Associate Principal, Strategy Consulting Services

andre.ballalai@iqvia.com

Oscar Courtney, Manager, Strategy Consulting

oscar.courtney@iqvia.com

Molecules were selected from US/EU approvals for novel oncologics and molecules indicated in rare disease from 2014-2021

Study Cohort Selection Criteria

Molecules were selected from a universe from IQVIA's global and EFPIA WAIT list. Filters were used to identify only orphan and oncology molecules. Further exclusions were based on rules defined and aligned with FIFARMA



IQVIA's global list and EFPIA WAIT list

Orphan and Oncology only

Exclude molecules based on rules defined

i.e., diagnostic tools, vaccines, drugs used in symptom relief (e.g., nausea) associated with oncologic treatment, molecules launched outside of the US/EU

- Molecules can have up to three marketing authorization dates: FDA, EMA, and local
- Orphan status may be determined by either the FDA or EMA

*Numbers used are for illustrative purposes only; ** Reflects the total after inclusions (+27) and exclusions (-9) based on updated exclusion rules

Acronyms: EFPIA: European Federation of Pharmaceutical Industries and Associations; WAIT: Waiting to Access Innovative Therapies; FDA: Food and Drug Administration; EMA: European Medicines Agency

Results from the study are shown in terms of different levels of availability

Availability Definitions



No Availability:

Not submitted, or in regulatory evaluation process

- Time required by local regulatory bodies evaluating market authorization submissions to make a final approval publicly available.

Approved, not available:

Commercially available, but not reimbursed

- As being approved by regulatory bodies, medicines are authorized to be commercialized in the country. In this stage, there is reimbursement from neither private nor public payers; patients typically pay full OOP. This is inclusive of managed access schemes.

Privately available:

Private market reimbursement

- Medicines available only in the private market for a limited number of patients. Typically, medicines are reimbursed by private payers (e.g., HMOs) or have total or partial coverage by private insurance policies.

Limited availability:

Reimbursement but not for a broad population

- The availability of medicines is limited to specific patient sub-populations, restricted to a limited number of treatment centers, or otherwise not granted access according to the full registered therapeutic indication.

Full availability:

Broad and national reimbursement

- Medicines are fully available at national level for a broad population in both public and private market. Full availability is frequently tied to national formulary listing, positive HTA recommendations, or central procurement.

Each geography in scope has a local definition of availability such that, to the extent possible, results can be compared regionally

		AR	BR	CL	CO	CR	EC	MX	PE
Availability Def.	Full	PAMI/ SURGE or PAMI and PMO	CONITEC and centralized purchases	Ley Ricarte Soto or GES	PBS-UPC	CCSS (LOM)	Essential list e.g., MSP, IESS	Compen-dium, and federal inst. purchases	PNUME, and RENETSA /RM purchases
	Limited	1+ country formulary and broad coverage by OSN / prepaid	CONITEC, no centralized purchasing	Limited FONASA reimburse ment, special programs	ADRES / MIPRES	Special purchases	Typically exception processes	Decentra-lized formularies	Not listed but with limited access
	Private	Broad prepaid coverage	ANS ROL placement	CAEC, ISAPREs	n/a	Prepaid plans	n/a	Large private formularies	n/a
Data	Public	SURGE, Drug Banks	CONITEC, ANVISA, ANS ROL	National websites, tenders	MinSalud, respective circulars	MOH, CCSS	MSP, IESS	Compen-dium, INEFAM, tenders	PNUME, IETSI, INEN
	IQVIA*	Retail, *non-retail*	Across channels	Retail, *non-retail*	Across channels	Retail, *non-retail*	Retail, *non-retail*	Across channels	Retail, *non-retail*
Caveats		Data coverage for sub-national plans not comprehe nsive	Relatively high visibility through available data	Private coverage data through CAEC is highly limited	Relatively high visibility through public data	Public data on approvals not available	Relatively high visibility through available data	Relatively high visibility through available data	Recent changes i.e., RENETSA and RM included

Definitions were aligned on and refined by the working group of local associations and IQVIA local teams

Where not otherwise stated, date of first sale was used to indicate time to reimbursement

Acronyms: PAMI:Programa de Asistencia Médica Integral; SURGE:Sistema Único de Reintegros por Gestión de Enfermedades ; PMO: Programa Médico Obligatorio; CONITEC: National Committee for Technology Incorporation; FONASA: Fondo Nacional de Salud; PBS-UPC:Plan De Beneficios En Salud Con Cargo A La UPC; CCSS: Caja Costarricense De Seguro Social; LOM: Lista Oficial de Medicamentos; MSP:Ministerio de Salud Pública ; IESS:Instituto Ecuatoriano De Seguridad Social; PNUME:Petitorio Nacional Único de Medicamentos Esenciales; RENETSA:Red Nacional de Evaluación de Tecnologías Sanitarias; ANVISA: Agencia Nacional de Vigilancia Sanitaria; MOH:Ministry of Health ; IETSI:Instituto de Evaluación de Tecnologías en Salud e Investigación; INEN: Instituto Nacional de Enfermedades Neoplásicas; CAEC:Cobertura Adicional para Enfermedades Catastróficas; GES: Garantías Explícitas en Salud

Factors influencing availability across markets

*Though this report does not aim to exhaustively identify and assess the impact of the multiple **factors that can influence availability across countries in LATAM**, there are several recurring themes that emerged through the research*

Commercial Partnerships

Oncology and Orphan drugs have a high number of emerging biotech's that have limited presence in the region, and typically require a local commercial partner to launch



Indication Sequencing

The study considers the approval and reimbursement date of the first indication to arrive in each market; but the first indication may not fully represent the availability status of a molecule

Role of the Private Market

Reimbursement in LATAM is bottoms-up, starting with private HMOs, then public sector before broad national formularies. In markets such as Brazil and Chile, a private market often delays public subnational access before broad public access

COVID Impact

During the COVID period, a decrease in high cost / specialty care HTA activity was observed, resulting in fewer molecules being included in both subnational and national formularies

Detailed Country Availability Definitions, as developed by CAEME - Argentina

Country	Availability	Definitions	Public Data	IQVIA Data
	Full[1,2,3]	*Multiple national formularies (PAMI and SURGE, or PAMI and PMO formularies) with reimbursement values aligned to treatment cost in case of bundled (e.g., SURGE) National Oncology Drug Bank*	**SURGE** *(Therapeutical Area Bundles Not Always Molecule Specific)* **Drug Banks** *Publicly Available Drug Banks of Relevant Obras Sociales (e.g., IOMA, OSECAC, OSDE)*	**Retail:** *Available* **Hospital / Non-Retail:** *Not broadly available*
	Limited[1,2,4]	*Listed in at least one of country formularies (e.g., PAMI, PMO, SURGE formularies), and Broad coverage by OSN and prepaid* *Conditions included on SURGE formulary, but with a treatment cost substantially higher than SURGE bundle are considered limited availability*		
	Only Private	*Broad coverage by prepaid plans*		
	Not Available	*ANMAT Approval, no broad coverage by prepaid plans, no national formulary or National Oncology Drug Bank listing* *Only OOP sales, mostly in the Retail Setting*	ANMAT Website	

[1]SUR / SURGE date of inclusion considered the date when the updated Superintendencia de Servicios de Salud (SSS) resolution is published
[2] PAMI contract execution considered as the date of PAMI formulary inclusion
[3] Full Availability: Consider the date of the most recent formulary inclusion as the date of full availability (i.e., if the product is first included on PAMI and further on SURGE, consider SURGE date as the reference for full availability
[4] Limited Availability: Consider the first formulary date as the reference for limited availability (i.e., if the product is included on PAMI but have a restricted coverage on SURGE, consider PAMI contract date as the reference for Limited Availability)